REGN

REGENERON PHARMACEUTICALS, INC.

REGN · CIK 872589 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$14.3B
20182025
Net Income$4.5B
20182025
Operating CF$5.0B
20182025
Free Cash Flow
20182025

Income Statement

MetricFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Revenue$14.3B$14.2B$13.1B$12.2B$16.1B$2.4B$2.2B$1.9B
Cost of Revenue$0.4B
Gross Profit
R&D Expense$5.9B$5.1B$4.4B$3.6B$2.9B$2.7B$3.0B$2.2B
SG&A Expense$2.7B$3.0B$2.6B$2.1B$1.8B$1.3B$1.8B$1.6B
Operating Income$3.6B$4.0B$4.0B$4.7B$8.9B$3.6B$2.2B$2.5B
Net Income$4.5B$4.4B$4.0B$4.3B$8.1B$1.1B$0.8B$0.8B
EPS (Basic)$43.07$40.90$37.05$40.51$76.40$10.90$7.25$7.58
EPS (Diluted)$41.48$38.34$34.77$38.22$71.97$10.24$6.93$7.15

Balance Sheet

MetricFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Total Assets$40.6B$37.8B$33.1B$29.2B$25.4B$17.2B$14.8B$11.7B
Current Assets$18.0B$18.7B$19.5B$15.9B$14.0B$9.8B$7.7B$6.4B
Cash & Equivalents$3.1B$2.5B$2.7B$3.1B$2.9B$2.2B$1.6B$1.5B
Total Liabilities$9.3B$8.4B$7.1B$6.6B$6.7B$6.1B$3.7B$3.0B
Current Liabilities$4.4B$3.9B$3.4B$3.1B$3.9B$2.7B$2.1B$1.4B
Stockholders' Equity$31.3B$29.4B$26.0B$22.7B$18.8B$11.0B$11.1B$8.8B

Cash Flow Statement

MetricFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Operating Cash Flow$5.0B$4.4B$4.6B$5.0B$7.1B$2.6B$2.4B$2.2B
Investing Cash Flow$-0.6B$-2.5B$-3.2B$-3.8B$-5.4B$-0.1B$-2.0B$-1.5B
Capital Expenditures
Financing Cash Flow$-3.7B$-2.2B$-1.8B$-1.0B$-1.0B$-2.0B$-0.3B$-0.1B